title: Acidic fibroblast growth factor accelerates the healing of acetic-acid-induced gastric ulcers in rats.
abstract: Acidic fibroblast growth factor (aFGF) was evaluated for the healing of acetic-acid-induced gastric ulcers in rats. The effect of aFGF on angiogenesis in the gastric ulcer bed was determined by the carmine dye infusion method, while its effect on gastric acid secretion was assessed in chronic gastric fistula rats. Oral treatment with aFGF, in the presence of heparin, reduced (ED50 value = 30.2 micrograms/kg/day) the acetic-acid-induced gastric ulcer area, when assessed 1 week later. aFGF was about 1,333-fold more potent than famotidine for healing such ulcers. At a dose of 200 micrograms/kg/day, aFGF increased the carmine density 3-fold and correspondingly reduced (80%) the gastric ulcer area. Thus, the ulcer healing effect of this agent involves angiogenesis in the gastric ulcer bed. This effect of aFGF appears to be unrelated to an inhibition of gastric acid secretion, as it was ineffective in chronic gastric fistula rats. In summary, oral aFGF significantly accelerates the healing of experimental gastric ulcers in rats. It may be a potent and effective agent for the treatment of peptic ulcers in humans.
authors.affiliation: Pharmacology Department, Rhône-Poulenc Rorer Central Research, Collegeville, Pa 19426-0107.
authors.forename: L R
authors.initials: LR
authors.lastname: Fitzpatrick
authors.forename: A
authors.initials: A
authors.lastname: Jakubowska
authors.forename: G E
authors.initials: GE
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Davis
authors.forename: M C
authors.initials: MC
authors.lastname: Jaye
authors.forename: C A
authors.initials: CA
authors.lastname: Dionne
mesh_terms: D000085:Acetates; D019342:Acetic Acid; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D000818:Animals; D000863:Antacids / Q000627:therapeutic use; D004338:Drug Combinations; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000627:therapeutic use*; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000098:blood supply; D008276:Magnesium Hydroxide / Q000627:therapeutic use; D009389:Neovascularization, Pathologic; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy*; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000085:Acetates; D000863:Antacids; D004338:Drug Combinations; D011994:Recombinant Proteins; D016220:Fibroblast Growth Factor 1; C013591:aluminum hydroxide, magnesium hydroxide, drug combination; D000536:Aluminum Hydroxide; D015738:Famotidine; D008276:Magnesium Hydroxide; D019342:Acetic Acid